Please use this identifier to cite or link to this item:
|Scopus||Web of Science®||Altmetric|
|Title:||Suspected DLIS interference in the dimension DGNA digoxin assay method and the clinical application of the revised digoxin target range|
|Citation:||Therapeutic Drug Monitoring, 2006; 28(3):454-457|
|Publisher:||Lippincott Williams & Wilkins|
|Morris, Raymond G., Jones, Terry E., Goldsworthy, Sharon J., Wagner, Tasma J, Ho, Helen, Horowitz, John D.|
|Abstract:||The authors present a case of an elderly female patient with heart failure and renal dysfunction treated with digoxin, where 2 commercial immunoassay methods (DRI, Microgenics, and DGNA, Dade Behring) showed a clinically very significant discrepancy on the same plasma sample, viz. 0.5 and 2.3 nmol/L, respectively. The sample was also referred to a third external laboratory that returned a result of 0.9 nmol/L using mFPIA (AxSYM, Abbott). Subsequent ultrafiltration (30,000 Dalton) on the sample essentially eliminated the difference, suggesting an interference from a large molecular weight compound(s), potentially the well-described digoxin-like immunoreactive substance(s) (DLIS). Although further study is required to verify that the DLIS implicated was indeed the interfering species, it does again highlight the importance of careful method selection in the clinical therapeutic drug monitoring laboratory to ensure that such well-established potential problems do not result in inappropriate dosage reduction with consequent lack of adequate drug exposure and serious clinical sequelae.|
therapeutic drug monitoring
|Description:||© 2006 Lippincott Williams & Wilkins, Inc.|
|Appears in Collections:||Aurora harvest 2|
Files in This Item:
There are no files associated with this item.
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.